Characterization of HIV-1 in the central nervous system during suppressive therapy by Dahl, Viktor
 DEPARTMENT OF MICROBIOLOGY, TUMOR AND 
CELLBIOLOGY 
Karolinska Institutet, Stockholm, Sweden 
 
CHARACTERIZATION OF 
HIV-1 IN THE CENTRAL 
NERVOUS SYSTEM DURING 
SUPPRESSIVE THERAPY 
Viktor Dahl 
 
 
Stockholm 2013 
 
 
 
  
 
All previously published papers were reproduced with permission from the publisher. 
 
Published by Karolinska Institutet. Printed by Larseric Digital Print AB 
 
© Viktor Dahl, 2013 
ISBN 978-91-7549-232-2
  
ABSTRACT 
Combination antiretroviral therapy (cART) is effective in suppressing HIV-1 RNA 
levels below the lower-limit of detection of clinical assays (<20-50 copies/mL) but is 
not curative and more sensitive assays can detect very low levels of HIV-1 RNA in 
plasma even after years of suppressive therapy. If treatment is stopped HIV-1 RNA 
levels soon increase and immunodeficiency continues to develop. This is due to the 
small amount of virions present in the blood during suppressive therapy that can infect 
new cells and cause viral rebound if treatment is stopped. These virions are produced 
by latently infected resting memory CD4+ T-cells that become reactivated. In addition, 
other cell types may be producing infectious virions during suppressive therapy. This 
needs to be explored to direct efforts for the eradication of all infected cells capable of 
producing virions in order to cure HIV-1. Since current HIV-1 therapy is life-long, 
costly and not without side effects a cure would be valuable from both an individual 
perspective as well as from a public health perspective. In this thesis we have, using 
very sensitive techniques for HIV-1 RNA quantification and sequencing, studied if 
HIV-1 also persists in the central nervous system (CNS) during suppressive therapy. 
 
We first analyzed paired cerebrospinal fluid (CSF) and plasma samples from elite 
controllers (who maintain plasma HIV-1 RNA levels at <40 copies/mL without cART) 
since they have been proposed to serve as a model for a functional cure. We found that, 
using a very sensitive assay that allows for HIV-1 RNA quantification down to less 
than 1 copy/mL, HIV-1 RNA could be detected at very low levels in both CSF samples 
and plasma samples. We then studied subjects on suppressive therapy with HIV-1 RNA 
levels below the lower limit of detection for clinical assays in both CSF and plasma 
(<40 copies/mL) and found that, using the same sensitive assay, HIV-1 RNA could be 
detected at very low levels in 17% of CSF samples and in 57% of plasma samples from 
these subjects. HIV-1 RNA could be detected in the CSF even after 10 years of 
suppressive therapy and the detection of CSF HIV-1 RNA was correlated to elevated 
levels of CSF neopterin, a marker for immune activation. We sequenced HIV-1 RNA 
in CSF and plasma from subjects on suppressive therapy and found a large fraction of 
replication incompetent hypermutants among the HIV-1 variants in CSF. In addition, 
we found one subject with genetically distinct variants in the CSF compared to plasma, 
consistent with virion production by two populations of cells, one possibly in the CNS.  
We did not see any signs of evolution among the sequences found in CSF during 
suppressive therapy. In addition, we found that subjects on suppressive therapy who 
had their ongoing treatment intensified by the addition of the integrase inhibitor, 
raltegravir, did not reduce CSF HIV-1 RNA levels or CSF immune activation. 
 
In conclusion, HIV-1 can be detected in the CSF even after years of suppressive 
therapy. The detection of HIV-1 in the CSF is correlated to intrathecal immune 
activation. The HIV-1 found in the CSF during suppressive therapy might be produced 
by cells in the CNS that need to be targeted in order to cure HIV-1. Since there are no 
signs of viral evolution among sequences found in the CSF during suppressive therapy 
and the CSF HIV-1 RNA levels are not affected by treatment intensification there does 
not appear to be any ongoing replication in the CNS during suppressive therapy.  
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1 INTRODUCTION 
1.1 THE HIV PANDEMIC 
1.1.1 The origin of HIV 
Human Immunodeficiency Virus (HIV) is the result of cross-species transmission of 
Simian Immunodeficiency Viruses (SIV) from other primates to humans. SIV belongs 
to a family of lentiviruses that can cause disease in a number of mammals including 
bovines, horses, sheep, felines and primates (primates can be further divided into 
prosimians and simians where simians contain monkeys and apes including humans). 
Among primates SIV can be found in over 40 different species [1], however, it is found 
exclusively in African monkeys and apes. This makes it likely that the introduction of 
lentiviruses in primates occurred after the split of lineages between African and Asian 
primates which is estimated to have occurred 6-10 million years ago [2]. It is not 
known when in this time-span the introduction occurred but geographically separated 
subspecies have been infected with the same type of SIV for at least 30 000 years 
proving that SIV has been circulating among African monkeys and apes for at least this 
long [3].  
 
HIV can be further divided into HIV-1 and HIV-2, representing cross-species 
transmissions of two different types of SIV. HIV-1 is the most common type of HIV 
(and will be primarily discussed in this thesis) whereas HIV-2 is much rarer and those 
infected with HIV-2 progress more slowly to AIDS.  HIV-1 is most closely related to 
the type of SIV (SIVCPZ) that is circulating among a subtype of the common chimpanzee 
found in Cameroon.  HIV-2 on the other hand is more closely related to the type of SIV 
(SIVSMM) found in sooty mangabeys in West Africa. There have been several separate 
introductions of SIVs to humans HIV. SIVCPZ appears to have been introduced to 
humans on at least four occasions and SIVSMM on at least 8 occasions [4].   
 
The four introductions of SIVCPZ gave rise to the four groups of HIV-1 that has so far 
been described (M, N, O and P). Group M has spread globally and represents more than 
99% of all HIV infections. Group M can be further divided into different subtypes and 
circulating recombinant forms that do not represent different cross-species events but 
appear to have evolved in humans. Subtype C is the most common subtype world-wide 
representing around 50% of all HIV infections whereas subtype B is the most common 
subtype in Europe and North America. As a result most studies (including those in this 
thesis) have been done on subtype B with the general caveat that the outcomes of these 
studies might not always be transferable to other subtypes.  
 
The cross-species transmission event that gave rise to the HIV-1 group M pandemic is 
estimated to have occurred in the beginning of the 20
th
 century in West-Africa [5, 6].  It 
has been proposed that the transfer of SIV to humans has occurred in the context of 
hunting of monkeys or apes (bush meat). Transmission would then have happened 
during butchering of the infected animal, perhaps when the hunter or butcher cuts 
himself or through exposure of blood from the infected animal on mucocutaneous 
surfaces. For HIV-1 group M this probably happened in southern Cameroon (Figure 1) 
since this is where the most closely related type of SIVCPZ is found circulating among 
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chimpanzees. The virus then somehow spread 700 km south to the inhabitants of 
Leopoldville (now Kinshasa in the Democratic Republic of Congo), at the time the 
largest city in the region and a hub of commerce. There HIV-1 group M started a local 
epidemic in the 1960s [6]. Then HIV-1 Group M was likely transferred to Haiti, maybe 
by Haitians returning home from work assignments in the Congo. From Haiti the 
epidemic then presumably spread to North America in the late 1960s and then across 
the world [7]. The first cases of acquired immunodeficiency syndrome (AIDS) caused 
by HIV-1 was described in USA in 1981 and HIV-1 was isolated in 1983 [8, 9]. 
 
Cross-species transmission of SIV has most likely occurred on many occasions but has 
not previously given risen to sustained human transmissions. A number of factors such 
as large scale injection-based treatment of various tropical diseases [10-12], 
urbanization [6] and increased prevalence of sexual transmitted disease [13] are factors 
that can have contributed to sustained transmission among humans and the spread of 
HIV-1 group M in West Africa making this single cross-species event the start of the 
pandemic. 
 
 
 
Figure 1. West-central Africa. Google maps (www.maps.google.com). 
 
1.1.2 The situation today 
Thirty million are estimated to have died from HIV infection and 34 million worldwide 
were estimated to be living with the infection by the end of 2011[14]. The prevalence 
varies greatly between regions. The most severely affected region is Africa south of 
Sahara where 69% of all infected people live and 1 out of 20 adults is HIV infected. 
The variation between countries within this region is substantial, and for example the 
prevalence in South-Africa is 17% whereas the prevalence in Nigeria is 4%.   
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Although the number of people living with HIV is greater than ever the number of 
people becoming infected (2.5 million in 2011) and the number dying from AIDS-
related disease (1.7 million in 2011) have been decreasing during the last years. This is 
partly due to the scale-up of interventions to prevent new infections and the more 
widespread use of combination antiretroviral therapy (cART). Since its introduction in 
1995 cART has saved more than 14 million life years in low- and middle income 
countries making it a major achievement of modern medicine. By the end of 2011 
cART reached 8 million people which for the first time was more than half (54%) of 
those eligible for treatment. Apart from the medical complications by HIV many of 
those infected are also suffering from stigma or discrimination. In conclusion, while the 
epidemic is slowing down and treatment has been scaled up, HIV/AIDS remains a 
massive global health problem.  
 
1.1.3 HIV in Sweden 
Around 10 000 people have been diagnosed with HIV (almost exclusively HIV-1) in 
Sweden since 1983 and around 6600 are living with HIV in Sweden today, 
corresponding to a prevalence of 0.06%. During 2012, 441 new infections were 
reported, 69% of those infected had contracted the infection outside of Sweden and 
59% through heterosexual transmission [15]. 
 
1.2 HIV-1 VIROLOGY 
1.2.1 Taxonomy, structure and genome 
HIV-1 belongs to the Lentivirus genus of the Retroviridae family. The other known 
human retroviruses belong to the Oncovirinae genus (Human T-cell leukemia virus) 
and Spumavirinae genus (Human foamy virus). HIV-1 has an envelope and contains 
two copies of positive sense ssRNA molecules which are linked at the 5’ end.  It has a 
conical nucleocapsid that surrounds the viral nucleic acid and the viral enzymes reverse 
transcriptase (RT), protease (PR) and integrase (IN). The nucleocapsid is surrounded by 
an envelope which consists mainly of the host cell lipid layer with viral glycoprotein 
gp41 linked to the external viral protein gp120 (Figure 2). 
 
The HIV-1 genome is approximately 9700 base pairs and codes for three major 
structural genes: group specific antigens (gag), polymerase (pol) and envelope (env). 
The Gag and Pol proteins are produced as Gag and Gag-Pol precursor polyproteins and 
are cleaved by PR into functional proteins. Gag encodes the precursor polyprotein 
which is further processed into p24 (capsid), p17 (matrix), p7 (nucleocapsid) and p6 
(nucleocapsid). Pol encodes the enzymes PR, RT and IN. Env encodes gp120 and the 
transmembrane protein gp41. In addition HIV-1 has two regulatory genes and four 
accessory genes: tat, rev, vif, vpr, vpu and nef (Table 1). 
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Figure 2. Schematic structure of the HIV-1 virion. Reprinted with permission from [16]. 
 
1.2.2 Replication 
Replication starts by the virus attaching to the target cell and is followed by the binding 
of the envelope protein gp120 to its primary receptor CD4 (Figure 3) [17, 18]. After 
binding to the target cell, conformational changes occur in gp120 allowing for binding 
to the co-receptor CCR5 or CXCR4 [19-22]. The viral envelope then fuses with the cell 
and reverse transcription (conversion of the viral ssRNA by RT to ssDNA) occurs in 
the partially dissolved capsid [23, 24]. Only one copy of ssDNA is produced from the 
two copies of ssRNA [25]. The RT can switch between the two strands of ssRNA 
which can lead to the occurrence of a new variant if the cell had been infected by two 
different viral variants (this is called recombination). As ssDNA is being synthesized 
by RT viral RNA is degraded by a domain of the RT. The dsHIV-1 DNA binds to Vpr, 
IN and p17 to form a pre-integration complex (PIC). The PIC is transported to the 
nucleus where HIV-1 DNA is integrated into the host chromosome by IN [26]. Viral 
DNA is primarily inserted into transcriptionally active regions of the cellular genome 
[27, 28]. Some HIV-1 DNA is not integrated but instead goes through a series of 
circularization steps generating 2-LTR (long terminal repeat) and 1-LTR circles which 
prohibits further viral replication  [26]. 
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Table 1. HIV-1 regulatory and accessory genes, proteins, location and function. 
 
Gene/Protein Expression In virion Function 
tat/Tat Early No Tat binds to the transactivation-
responsive region in the 5' end of the 
integrated viral DNA  and enhances 
transcription 
 
rev/Rev Early No Rev binds to rev responsive element and 
facilitates the transport of unspliced or 
partially spliced mRNA out of the 
nuclesus for translation 
 
nef/Nef Early Yes Down regulates CD4 and MHC I and II 
of infected cells to avoid immune 
response 
 
vpr/Vpr Late Yes Involved in transport of pre-integration 
complex into the nucleus and prevents 
cell division 
 
vpu/Vpu Late No Induces degradation of CD4 and 
enhances the release of virions 
vif/Vif Late Yes Inhibits APOBEC thus preventing 
hypermutation 
 
After integration HIV-1 can go into a latent state where it is not transcribed or, which is 
the exceedingly more common, replication continues by transcription of the integrated 
HIV-1 DNA by the host RNA polymerase II. HIV-1 RNA transcription is mediated 
through the binding of cellular transcription factors, most importantly NFkB to a 
promoter region in the 5’ LTR region of the HIV-1 genome. The first transcript is a full 
length copy of the viral RNA. This early transcript is then spliced into mRNAs that are 
translated into the viral proteins Tat and Rev. Tat binds to the transactivation-
responsive region which is situated downstream from the 5’ LTR region where Tat 
enhances HIV-1 transcription thus creating a positive feed-back loop. Rev binds to the 
rev responsive element in the env region of the unspliced, or partially spliced, HIV-1 
mRNA and facilitates transport of these molecules out of the nucleus for translation. 
During late transcription alternative splicing gives longer Gag, Gag-Pol, Env, Vif, Vpr, 
Vpu and full length HIV-1 RNA. All translation of viral mRNAs occurs in the 
cytoplasm near the endoplasmatic reticulum (ER) by the normal cellular transcription 
machinery. The envelope protein gp160 is processed in the ER and the Golgi complex 
where it is cleaved into gp41 and gp120 and glycosylated. The assembly of a new 
virion containing the viral the proteins Gag, Gag-Pol, Vif and Vpr and the full-length 
viral RNA takes place at the cellular membrane. The new virion is then released by 
budding, taking a part of the host cell membrane as the viral envelope. The final step in 
the viral replication is the maturation step where the viral enzyme PR cleaves the Gag 
and Gag-Pol polyproteins into matrix, capsid, nucleocapsid and p6 proteins. These 
proteins form the mature nucleocapsid and matrix. The viral protease also cleaves the 
Gag-Pol polyprotein into the viral enzymes PR, IN and RT after the viral particle has 
budded from the infected cell making the particle infectious [29].  
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Figure 3. HIV-1 replication. Reprinted with permission from [30]. 
 
1.2.3 Genetic variation 
Like all RNA viruses HIV-1 is a genetically diverse virus. This is partly due to the error 
rate of HIV-1 during replication (approximately one error per 3x10
-5
 bases) which, on 
average, results in 0.3 mutations in each new virion produced. These errors can be 
attributed to the error-prone RT that lacks proof-reading but also to the host cell RNA 
polymerase and G to A mutations generated by apolipoprotein B messenger RNA 
editing enzyme catalytic polypeptide-like (APOBEC) proteins. The error rate is 
comparable to what is seen in other RNA-viruses [31]. Due to the number of infected 
cells a great number of new virions (around 10
9
) are produced every day. This means 
that every possible point mutation occur in an infected individual every day. Why 
certain mutations become fixed is partly due to classic Darwinian evolution where 
some mutations that give the virus an increased fitness become fixed (positive 
selection) whereas other mutations that decrease the fitness or render the virus 
replication incompetent disappear (negative selection). Some mutations that do not 
affect fitness will also become fixed by chance (neutral evolution) [32].  
 
Another factor that contributes to the genetic diversity of HIV-1 is recombination. If 
one cell is infected by two variants of HIV-1 and these two variants happen to be 
assembled in the same virion then RT can switch between the RNA from these two 
variants during the subsequent infection of a new cell, this generates HIV-1 DNA 
which is a combination of the two variants. Even though cells double infected cells 
appear to be rare the relative importance of this phenomenon is illustrated by the fact 
that more than 20% of all circulating HIV-1 variants are recombinants of different 
subtypes [33, 34].  
   7 
 
Point mutations and recombination in combination with the large number of virions 
produced each day and the long duration of infection generates an exceptional genetic 
diversity [31]. Amazingly the genetic diversity within a single HIV-1 infected 
individual is greater than the diversity of all influenza virus isolates worldwide within a 
year [35]. The great diversity generated during HIV-1 replication, which in the env (the 
gene with the most diversity) can reach 25-35%, has made it possible to track the 
spread of HIV-1 globally, between individuals and to some extent within individuals by 
phylogenetic analyses [7, 36, 37]. 
 
1.3 HIV INFECTION 
1.3.1 Transmission and prevention  
HIV-1 can be transmitted after exposure to mucosal surfaces, most commonly through 
vaginal or anal intercourse. Another route of infection is from an infected mother to her 
child, either in utero, during labor or through breast feeding. The virus can also spread 
through percutaneous inoculation, either through intravenous drug use or nosocomially 
by contaminated needles or blood products.  
 
Heterosexual HIV-1 transmission is the most common form of transmission  and 
accounts for 70% of infections world-wide despite that the risk for transmission is 
rather low (usually well below 1%, with a slightly higher risk of transmission from  
male to female compared to transmission from  female to male) [38]. The risk for 
sexual transmission is increased by co-existing genital ulcers [39]. It is also strongly 
correlated to the HIV-1 RNA levels in plasma, a tenfold increase in plasma HIV-1 
RNA levels results in 2.5 fold risk of transmission [40, 41]. Consequently a reduction 
in the HIV-1 RNA levels in plasma by cART is a very effective intervention to prevent 
transmission and can almost completely prevent transmission in sero-discordant 
couples [42, 43]. Another intervention that has been shown effective to prevent 
transmission is male circumcision which reduces the risk of transmission to the 
circumcised man by 60% [44, 45]. Proper use of condoms also greatly reduces the risk 
for sexual transmission. 
 
Where available, cART, to the mother and the infant, Caesarean section and the 
avoidance of breast feeding can almost completely prevent mother-to-child 
transmission [46].  In low- and middle income countries where this is not affordable or 
feasible various combinations of antiretrovirals (ARVs) can at least greatly reduce the 
risk of transmission [47].  Single use needles and testing of blood products can reduce 
nosocomial transmission and needle exchange programs can reduce the rate of HIV-1 
transmission among intravenous drug users (IDUs) [48].  
 
Transmission of HIV-1 and thus establishment of infection by only a single virion 
appears to be the norm, occurring in 80% of the heterosexual transmission events. 
Infection with multiple HIV-1 variants occurs more frequently during mother-to-child 
transmission as well as during transmission among men who have sex with men and 
among intravenous drug users [49-53]. 
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1.3.2 Cells and tissues 
HIV-1 uses the CD4 receptor as its main receptor for infecting a cell and this, and the 
co-receptors used, determines which cells that become infected [54, 55]. The CD4 
receptor is mainly expressed on the surface of CD4+ T-cells (naïve and memory) and 
this cell type is the primary target for HIV-1.  Apart from its main receptor HIV-1 uses 
CCR5 or CXCR4 as co-receptors. The CCR5 expression is higher on CD4+ memory 
T–cells (making this subset the primary target) while naïve CD4+ T-cells express 
CXCR4 [56-60]. This reflected by the infection frequency of each subset, in peripheral 
blood the infection frequency of memory CD4+ T-cells is 0.01-1% while the infection 
frequency for naïve CD4+ T-cells is a tenfold lower [60-62]. Almost exclusively the 
infection is established by a virus using CCR5 [49, 63]. Later during infection the co-
receptor usage of the virus can change so variants which use either both CXCR4 and 
CCR5 or CXCR4 exclusively can arise [64-67]. The appearance of viral variants that 
uses CXCR4 as receptors is linked to accelerating disease progression but it is 
unknown if it is the cause or a consequence of this.  
 
Apart from CD4+ T-cells monocytes, macrophages, NK-cells and dendritic cells have 
been proposed to be infected by HIV-1 in vivo. There are however still uncertainties 
regarding this and, if infected at all, whether these cells actually can produce new 
virions (productive infection).  According to some reports monocytes can be infected in 
vivo [68-71] while other investigators have not found infected monocytes in vivo 
despite extensive sampling [34]. Monocytes circulate for 1-3 days before they migrate 
into tissues and become macrophages [72]. That macrophages become infected in vivo 
is less controversial [73-77].  In addition, NK-cells can also be infected in vivo [78]. 
Dendritic cells are able to capture the virus on their cell surface and transport it to 
lymphatic tissue where it can infect CD4+ T-cells but it is less clear if dendritic can be 
infected themselves [79, 80].  
 
The CD4+ T-cell is the primary target for HIV-1 infection and can be found in various 
tissues throughout the body. For practical reasons infected CD4+ T-cells found in blood 
have been studied the most, but they represent only 2% of the body´s lymphocytes [81]. 
The gut-associated lymphoid tissue (GALT) is the largest lymphoid organ in the body 
harboring 60% of the lymphocytes, 40% of them being CD4+ T-cells [82-85]. Massive 
depletion of CD4+ T-cells has been found in this compartment during early HIV-1 
infection [83, 84]. Lymph nodes throughout the body also harbor CD4+ T-cells and 
lymph nodes have been found to contain higher concentrations of both HIV-1 RNA and 
HIV-1 DNA than peripheral blood [86-88].  
 
1.3.3 Immune response 
The body has two lines of defense against HIV-1 infection: the innate immune system 
(including restriction factors) and the adaptive immune system. Restriction factors are 
cellular factors which inhibit HIV-1 replication. Those that so far have been described 
to be protective are: 
 
1.  The APOBEC families of proteins, in particular APOBEC3G. They are 
expressed in virtually all human tissue [89, 90]. APOBEC3 can become 
integrated in the viral particle and is transferred to the target cell where it forms 
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a complex with the viral RT. There it deaminates cytidine residues in the 
negative strand viral DNA. This can result in up to 10% hypermutations of 
guanosine to adenosine in the positive strand sequence which renders the 
generated viral DNA unable to produce infectious virions [91, 92]. APOBEC is 
antagonized by the viral protein Vif [93-95]. 
2. Trim5α binds to the capsid after viral entry and accelerates capsid 
fragmentation and disrupts the structure of the RT [96]. Trim5α from old world 
monkeys effectively inhibits infection with HIV-1 and is a major reason for 
why old world monkey cannot be infected with HIV-1 [96]. 
3. Tetherin causes virions to remain trapped at the cell surface and thereby 
prevents the release of virions [97]. Tetherin is counteracted by the viral protein 
Vpu [98].       
 
Like other ssRNA viruses HIV-1 triggers the innate immune receptors TLR7 and TLR8 
which results in potent activation of dendritic cells and the release of type 1 interferons 
and tumor necrosis factor α. This shuts down viral replication in infected cells and 
activates other parts of the immune system [99, 100]. Among the cells of the innate 
immune system NK-cells appear to be most important for the control of HIV-1 
infection. This reflected by how some variants of NK-cell receptors are correlated to a 
slower progression towards AIDS [101, 102].  
 
HIV-1 infected individuals are able to mount a robust CD8+ T-cell response against 
HIV-1 when measured in vitro, yet full viral control is not achieved in vivo [103-105]. 
This could be due to that the CD4+ T-cell response (which is necessary for an effective 
CD8+ T-cell response) is deeply impaired during HIV-1 infection [103, 104, 106]. 
Certain HLA-alleles (especially HLA-B57) are linked to a slower progression of 
disease indicating that the CD8+ T-cell response can at least partially control infection 
in some individuals. [107, 108]. Initially the CD8+ T-cell response is narrow, in regards 
to which epitopes it targets, but it tends to broaden over time [109-112]. The virus 
constantly evolves to avoid the CD8+ T-cell response and escape mutations are seen 
within a month of infection [111]. 
 
The B-cell response to HIV-1 develops within the first weeks of infection [113]. These 
early antibodies do not seem to have any effect on HIV-1 RNA levels or contribute to 
immune pressure on the viral population [49, 113]. Even though the antibody response 
becomes more potent and broaden over time the B-cell response in general appears to 
be less associated with control of infection compared to the T-cell response [114-116]. 
The presence and breadth of the neutralizing antibody response is not associated to 
HIV-1 RNA levels and does not impact progression to AIDS [115-117].  
 
1.3.4 Pathogenesis 
HIV-1 infection is characterized by the progressive loss of CD4+ T-cells which 
eventually leads to immunodeficiency and death from opportunistic infections. The 
cause of this progressive loss of CD4+ T-cells is unclear. A recent study suggests that 
the integration of viral DNA triggers apoptosis in infected cells [118]. Another possible 
mechanism is the CD8+ T-cell mediated killing of infected cells. Indirect evidence for 
this is that the depletion of CD8+ T-cells in infected animal models lead to a 100-fold 
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increase of viremia, presumably since infected CD4+ T-cells can produce virions for a 
longer time if not killed by CD8+ T-cells [119, 120].  
 
Another important feature of HIV-1 infection, apart from the loss of CD4+ T-cells, is 
immune activation [121]. In addition to being activated the immune system bears 
markers of ageing and exhaustion [122-124]. Expression of markers for immune 
activation are important indicators of disease progression during untreated infection 
[121, 125, 126]. There are several factors that can contribute to immune activation 
during HIV-1 infection: 
 
1. The virus itself is recognized by the immune system. 
2. Opportunistic infections such as cytomegalovirus are able to replicate during 
HIV-1 induced immune deficiency which could lead to immune activation 
[127]. 
3. Damage caused to the mucosal CD4+ T-cells around the gut leads to 
translocation of microbial products from the gut to the systemic circulation 
[128, 129]. 
 
The immune activation is rapidly reduced (but not entirely eliminated) when HIV-1 
RNA levels are suppressed after the initiation of cART [130, 131]. In primates, such as 
sooty mangabeys, where SIV does not lead to immunodeficiency no immune activation 
or loss of CD4+ T-cells is seen [132, 133].   
 
1.3.5 Progress of HIV-1 infection  
After infection an asymptomatic period of 1-2 weeks follows when the virus replicates 
at the site of infection and in local lymph nodes. During this phase HIV-1 RNA is not 
detectable in the blood (measuring HIV-1 RNA levels is a proxy for measuring the 
amount of HIV-1 virions), no immune response is measurable and the infected 
individual remains asymptomatic [83-85, 134-137]. Then a peak in HIV-1 RNA levels 
follows (up to 10
7 
copies of HIV-1 RNA/mL) as the infection spreads throughout the 
body. This is likely due to the large number of available target cells such as CD4+ T-
cells in gut-associated lymphoid tissue (GALT) and peripheral lymphoid tissues and the 
lack of immune response against the virus. During this phase around 50% of infected 
subjects experience flu-like symptoms such as fever, enlarged lymph nodes and 
occasionally a rash [138]. After the initial depletion of a large number of target cells 
and the emergence of an immune response the HIV-1 RNA levels drop rapidly, by 
about a 100-fold, and stabilizes around a set-point. The events of early HIV-1 infection 
have been classified by Fiebig and colleagues based on the order of appearance of 
various markers for HIV-1 infection (Figure 4) [139].  
 
After the viral set-point is established a period of asymptomatic infection follows. This 
period consists of slowly declining CD4+ T-cell levels and relatively stable HIV-1 
RNA levels (Figure 5).  Although HIV-1 RNA levels and CD4+ T-cell counts only 
slowly change during this time, giving  the impression of this being a stable phase, this 
period consist of the production of a large amount of viral particles each day, massive 
killing of CD4+ T-cells and the body’s constant struggle to replenish these  cells. This 
period is on average 10 years, but shows considerable inter-individual variation [140]. 
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The set-point viral HIV-1 RNA level and the degree of immune activation as well as 
the presence of certain HLA-alleles correlates to the time before development of AIDS 
[107, 108, 141]. The stage of disease can be classified either based on the WHO criteria 
or the CDC criteria [142, 143]. Generally AIDS is considered to have developed either 
when the CD4+ T-cell count falls below 200 cells/µL or by the appearance of certain 
opportunistic infections such as toxoplasmosis of the brain, pneumocystis jiroveci 
pneumonia,  candidiasis of the esophagus, trachea, bronchi or lungs and Kaposi's 
sarcoma. 
 
 
Figure 4. Laboratory staging of acute and early HIV-1 infection based on the appearance of various 
biological markers. The average durations and 95% confidence intervals (parentheses) of the different 
stages are shown in the inset. Reprinted with permission from [144]. 
 
1.3.6 Elite controllers 
Elite controllers are a rare group (<1%) of HIV-1 infected individuals who, without 
cART, can maintain HIV-1 RNA levels in plasma below the lower-limit of detection 
for clinical assays (usually defined by <50 copies of HIV-1 RNA/mL) [145, 146]. 
Using very sensitive assays one can however detect low levels of HIV-1 RNA in 
plasma [147, 148].  Novel escape mutations can be found suggesting that replication 
occurs at a low-level [149]. Consistent with that HIV-1 RNA levels are directly 
correlated to disease progression most elite controllers do not progress to AIDS, 
although with some exceptions [150]. Replication  competent virus can be isolated 
from most elite controllers, though in some cases elite control has occurred since the 
subjects had been infected with a defective virus [151, 152]. The CD8+ T cells are 
thought to play an important role for control and certain HLA class I alleles such as 
HLA-B5701, HLA-B5703 and HLA-B27 have all been associated with control. [146, 
153-155]. As compared to non-controllers, freshly isolated CD8+ T cells from 
controllers also have a higher capacity to inhibit HIV-1 replication in infected CD4+ T 
cells [156]. No single factor, however, seems to be completely protective, nor is there 
one that is strictly required.  
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Figure 5. Time course of typical HIV-1 infection. Patterns of CD4
+
 T cell decline and viremia vary 
greatly from one subject to another. Reprinted with permission from [31]‏. 
 
1.3.7 The central nervous system 
HIV-1 enters the central nervous system (CNS) during the first weeks of infection and 
can be detected in the cerebrospinal fluid (CSF) throughout the subsequent course of 
untreated infection [157-161]. It is thought to enter the CNS by the so called “Trojan 
horse model”, the migration of an infected cell (often suggested to be an infected 
monocyte) into the CNS. This model was originally proposed for visna virus, another 
type of lentivirus found in sheep [162]. Since there is no final evidence that monocytes 
are infected by HIV-1 in vivo it is more likely that CNS infection is established by the 
migration of an infected CD4+ T-cell into the CNS, or possibly by the transport of free 
virions across the blood-brain barrier.  
 
Usually the HIV-1 RNA levels are about a 10-fold lower in CSF than in plasma, 
although this can vary considerably between individuals [159, 160, 163, 164]. Viral 
populations in the CSF and blood can follow separate evolutionary pathways and 
compartmentalize in some subjects [165-174]. It appears that the changes are adaptive, 
perhaps an adaptation to better replicate in cells in the CNS or perhaps changes that 
leads to an increased fitness since there is less immune response against HIV-1 in the 
CNS [166, 173, 175]. 
 
There has been considerable discussion about which cell types in the CNS can be 
infected and produce virions. Most agree that pervivascular macrophages (derived from 
circulating monocytes migrating into the CNS) can be infected and produce virions, 
this is possibly also the case with microglia (also of monocyte origin) whereas 
astrocytes likley can be infected but do not produce virions in vivo [77, 176, 177].  
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As in the periphery HIV-1 infection of the CNS is characterized by immune activation. 
This is reflected in the elevation of several markers for inflammation in the CSF such 
as CSF white blood cell, CSF neopterin (a marker for macrophage activation), 
CCL2/MCP1 and CXCL10/IP10 chemokines (which stimulate the migration of 
monocytes and lymphocytes into the CNS) [178]. In addition to elevated markers for 
immune activation markers for neuronal damage such as neurofilament light chain 
protein (NFL), and total tau proteins are also elevated in the CSF while amyloid 
precursor proteins are decreased consistent with altered neuronal meatbolism [179-
182].  
 
Table 2. Criteria for HIV associated neurocognitive disorder (HAND). Adapted from [177]. 
 
Diagnostic entity Cognitive performance Functional status 
Normal Normal Normal 
Asymptomatic 
neurocognitive 
impairment  
Acquired impairment in at least two 
cognitive domains (<1 SD) 
No perceived impact on daily function 
Mild neurocognitive 
disorder  
Acquired impairment in at least two 
cognitive domains (<1 SD) 
Perceived interference with daily 
function to at least a mild degree (work 
inefficiency, reduced mental acuity) 
HIV-associated 
dementia  
Acquired impairment in at least two 
domains, typically in multiple domains 
with at least two domains with severe 
impairment (<2 SD) 
Marked impact on daily function 
 
Untreated HIV-1 infection is commonly associated with neurological symptoms such 
as attention and memory deficits, motor impairments and personality changes [183]. 
According to current nomenclature the neurological symptoms associated with HIV-1 
should be referred to as HIV Associated Neurocognitive Disorder (HAND) and could 
be further classified into three subtypes depending on the degree of impairment on 
neuropsychological testing and functional disability (Table 2) [184]. The damage that 
HIV-1 causes to the brain is seen as diffuse brain atrophy with large ventricles, low 
grade inflammation with microglanodules, perivascular lymphocyte cuffing, 
multinucleated cells, patchy demyelination and white matter gliosis [185, 186]. Since 
HIV-1 does not infect neurons the neurological symptoms that can occur during HIV-1 
infection must be due to indirect damage to the neurons. Two mechanisms for how this 
occurs have been suggested and proven to occur in vitro but it remains unclear which is 
the most important factor in vivo [176].   
 
1. Viral proteins such as gp120 and Tat may be directly toxic to neurons. 
2. Toxicity may be mediated by release of neurotoxic factors such as quinolonic 
acid, tumor necrosis factor and arachidonic acid metabolites by infected and 
uninfected cells responding to infection. 
 
Untreated HIV-1 infection also predisposes to opportunistic infections in the CNS in 
those with more severe immune deficiency. 
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1.4 THERAPY 
1.4.1 Drugs 
Most ARVs have their effect by inhibiting the RT. The ARVs that inhibit the RT can be 
subdivided into nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) (Table 3). NRTIs lack a 3’ hydroxyl group 
which results in termination of the synthesis of viral DNA when a NRTI is incorporated 
[187]. NNRTIs inhibit RT through binding proximal to, but not overlapping, the active 
site of the RT [188, 189]. 
 
This binding changes the spatial structure of the active site and reduces RT activity 
[188]. Due to differences in the RT structure NRTIs inhibit HIV-2 replication whereas 
NNRTIs do not [188]. The third major drug class is protease inhibitors (PIs). They have 
their effect by inhibiting PR which cleaves Gag and Gag-Pol necessary for virion 
maturation. PIs are large peptide-like molecules that are quickly degraded. Therefore, 
ritonavir is co-administered to “boost” PI treatment by inhibiting the enzyme that 
degrades PIs which prolongs the activity of the PI [190, 191].  These are the major drug 
classes of ARVs but drugs that target other parts of the viral life cycle have also been 
developed. CCR5 antagonists can block binding of HIV-1 that uses CCR5 as a co-
receptor [192], fusion inhibitors can block the fusion of the virion and the cell [193] 
and integration of HIV-1 DNA into the genome of the infected cell genome can be 
prevented by inhibitors of viral integrase [194, 195]. 
 
1.4.2 cART 
As previously discussed, HIV-1 is a genetically diverse virus therefore variants with 
reduced susceptibility to an ARV can exist as minor variants before treatment is 
initiated or quickly evolve if replication is not completely inhibited by cART [196]. 
Mathematical modeling suggests that a treatment regimen should consist of a 
combination of ARVs where at least three mutations are required for resistance to 
develop to prevent the emergence of resistant variants [196]. This is consistent with 
clinical experience of resistance development during mono- or dual therapy, and 
therefore ARVs are given in combinations of at least three different drugs. According 
to current Swedish guidelines, first line treatment should consist of two NRTIs and one 
PI or one NNRTI (US guidelines also give the option of combining two NRTIs with an 
integrase inhibitor) [197, 198]. Swedish guidelines recommend that treatment should be 
initiated when the CD4+ T-cell count is between 350-500 cells/mm
3
 whereas US 
guidelines suggests that treatment should be offered regardless of CD4+ count.  
 
Where available cART has greatly reduced the morbidity and mortality from 
immunodeficiency associated with HIV-1 infection [199-202]. However cardiovascular 
disease, liver disease and some non-AIDS related malignancies are over-represented 
among HIV-1 infected individuals receiving suppressive cART [203-208]. The 
mechanisms behind these pathologies are not fully elucidated but they appear to some 
extent to be linked to the presence of low-grade inflammation during cART [209, 210]. 
Despite cART, some individuals do not achieve normal CD4+ T-cell counts (immune 
non-responders) perhaps due to fibrosis of the lymphoid tissues [211, 212].   
   15 
 
Table 3. ARVs approved by Food and Drug Association (FDA) and European 
Medicines Agency (EMA). 
 
Drug Approved by FDA/EMA Mechanism 
 
NRTIs 
  
abacavir (ABC) 1998/1999 NRTIs lack a 3’ 
hydroxyl group 
which results in 
termination of the 
viral DNA copy 
when a NRTI is 
incorporated  
didanosine (ddI) 1991* 
emtricitabine (FTC) 2003/2003 
lamivudine (3TC) 1995/1996 
stavudine (d4T) 1994/1996 
tenofovir (TDF) 2001/2002 
zalcitabine (ddC) 1992 
zidovudeine (AZT) 1987/1987 
 
NNRTIs 
  
delaviridine (DLV) 1997/- NNRTIs inhibit RT 
through binding 
proximal to, but not 
overlapping, the 
active site of the RT 
efavirenz (EFV) 1998/1999 
etravirine (ETR) 2008/2008 
nevirapine (NVP) 1996/1998 
Rilpivirine 2011/2011 
 
Pis 
  
Atanzavir 2003/2004  
Darunavir 2006/2008 PIs  inhibit PR 
which cleaves Gag 
and Gag-Pol 
necessary for virion 
maturation.  
Fosamprenavir (fAMP) 2003/2004 
Indinavir (IDV) 1996/1996 
Lopinavir (LPV) 2000/2001 
Nelfinavir (NFV) 1997/1998 
Saquinavir (SQV) 1995/1996 
Tipranavir (TPV) 
 
2005/2005 
Entry inhibitors   
Maraviroc (MVC) 2007/2007 Blocks binding of 
HIV-1 to co-
receptor CCR5.  
Fusion inhibitors   
Enfuvirtide (T-20) 2003/2003 Prevents fusion by 
binding to gp41. 
Integrase inhibitors   
Raltegravir (RAL) 2007/2007 Prevents integration 
by binding to the 
complex between IN 
and the viral 
genome. 
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1.4.3 Resistance  
Drug resistance can either be transmitted, pre-existing or develop during cART if 
therapy is not fully suppressive. In Sweden transmitted drug resistance is present in 
approximately 5% of new infections, in Europe in approximately 8% and in the US 
transmitted drug resistance is estimated to occur in 15% of new infections [213-215].  
Resistance can also develop during cART that is not fully suppressive due to lack of 
adherence or due to drug interactions. Generally, resistance develops quicker for NRTIs 
and NNRTIs than for PIs. For NRTIs (more particular 3TC or FTC) mutations such as 
M184V/I and K65R changes the binding site for the NRTI and thereby prevents it from 
being incorporated in the elongating chain [216, 217] whereas the thymidine analogue 
mutations (M41L, L210W, T215Y, D67N, K70R, T215F and 219E/Q) seem to remove 
the incorporated NRTI (AZT and d4T) [218, 219]. Resistance against NNRTIs can 
occur through the emergence of single mutations (K103N and Y181C) [220, 221]. The 
emergence of NRTI-resistance mutations is often associated with a greater reduced 
fitness for the virus than NNRTI-mutations. Resistance to PIs requires the accumulation 
of several mutations and is therefore less likely to develop [222]. 
 
1.5 PERSISTANCE 
1.5.1 Dynamics 
With the assumption that cART prevents all (or almost all) infection of new cells, but 
does not affect the life-span of the infected cells, some conclusions about the 
population of infected cells can be drawn from the decay of the HIV-1 RNA level once 
treatment is initiated. First there is a rapid phase of decay where the level drops to 1-
10% of the pre-therapy level (Figure 6). This phase corresponds to the decay of a 
population of cells with a half-life of 1-2 days, most likely activated CD4+ T-cells that 
where already productively infected when therapy was initiated. This is followed by a 
second phase of decay with a half-life of ca 2 weeks. This phase is often attributed to 
macrophages or possibly partially activated CD4+ T-cells, but this is uncertain [223]. 
Then the HIV-1 RNA level falls below the lower limit of detection for assays used in a 
clinical setting (<20-50 copies of HIV-1 RNA/mL) [224-226].  Using more sensitive 
assays it can be demonstrated that the second phase of decay is followed by a third with 
a half-life of 39 weeks which is followed by a plateau phase where HIV-1 RNA at a 
level of approximately 3 copies/mL persists even after years of suppressive therapy 
[148, 227, 228]. The on-therapy plasma HIV-1 RNA levels are correlated to levels of 
pre-therapy plasma HIV-1 RNA, however, the potency of the treatment regimen does 
not appear to affect the levels of persistent viremia [229].  
 
HIV-1 virions in blood have a half-life of only minutes so the occurrence of HIV-1 
RNA in blood means virions are constantly produced (methods used for detecting HIV-
1 RNA measure virion-associated HIV-1 RNA) [230]. How HIV-1 virions are 
produced during suppressive therapy has been a question of debate. Initially it was 
believed that this was due to low-level replication occurring despite cART [227]. The 
replication would then occur in the presence of ARVs or in cells, tissues or anatomical 
compartments where ARVs are at suboptimal concentrations such as in the CNS.  
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Figure 6. Decay dynamics of plasma HIV-1 RNA during cART. Upon initiation of cART, viremia 
decays in multiple overlapping phases, which reflects the turnover of cells infected prior to cART with 
different half-lives. Blue = above clinical limit of detection (LOD). Red = below clinical LOD (ie, 
detectable by SCA or other sensitive assays). Dotted lines = theoretical decay slopes. Reprinted with 
permission from [231]. 
 
Alternatively, cART inhibits all or almost all viral replication and the occurrence of 
HIV-1 virions during suppressive therapy is due to the production of virions from long-
lived infected cells that became infected before the initiation of cART. Most studies 
favor the latter explanation. In summary: 
 
 Resistance mutations usually do not emerge during suppressive cART which 
would likely happen if there were full cycles of replication. [232-236].  
 Most studies find no substantial signs of viral evolution (a consequence of 
replication) during suppressive therapy [233, 236-239]. When signs of viral 
evolution are found it is hard to exclude the possibility that the “new variants” 
found during suppressive therapy were actually present pre-therapy but not 
found because of limited sampling or that some subjects have had short periods 
of non-adherence to therapy.   
 The on-therapy HIV-1 RNA levels are not related to the potency of the 
treatment regimen [229]. This would have been expected if there was ongoing 
replication in some tissues or compartments since different drugs penetrate 
more or less well different compartments and tissues. 
 Most studies which have intensified cART with and additional drug have not 
seen any effect on plasma HIV-1 RNA levels [240-243] . One study observed 
an effect on 2-LTR circles which could indicate that ongoing-replication was 
inhibited in the subset of subjects who were on a PI-based treatment regimen 
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[244]. However, it is debated if 2-LTR circles are a reliable indicator of HIV-1 
replication. 
 When treatment is stopped the variants that emerge do not have a close 
relationship to the variants that existed just before treatment was initiated. 
Rather it appears to be a stochastic reactivation of variants that previously have 
existed and have been “archived” in resting memory CD4+ T-cells [245, 246]. 
 
This does not rule out replication in other compartments during suppressive therapy. A 
recent study found an increase in unspliced HIV-1 RNA in the GALT during raltegravir 
intensification suggesting that some ongoing replication in this site was inhibited by 
intensifying treatment [247]. However, another study found no sign of viral evolution 
in cells isolated from GALT during suppressive therapy [248]. The CNS has also been 
proposed to be a site where HIV-1 replication can continue, this is discussed further 
below.  
 
1.5.2 Cells and tissues 
The cells that are capable of producing virions during suppressive therapy (often 
referred to as the reservoir) are of great interest. Presumably it is these cells that need to 
be targeted and eliminated in order to eradicate HIV-1. Phylogenetic analyses of virions 
in the plasma during suppressive therapy revealed that the sequences of the plasma-
derived virus intermingles with the HIV-1 variants found in a reservoir of  infected 
resting memory CD4+ T-cells. This finding suggests that the source of these plasma-
derived virions is infected resting memory CD4+ T-cells [236]. These cells were then 
presumably infected when they were active but returned to a resting state before they 
died. These latently infected cells are quite rare (1/10
6
) but remain during cART with a 
half-life of at least 44 months which indicates that cART will not clear HIV-1 from an 
infected individual within their lifetime [249-252]. Some evidence suggests that the 
stability of this reservoir is maintained by homeostatic proliferation of latently infected 
CD4+ T-cells driven by IL-7 and IL-15 [253]. Phylogenetic  analyses have shown that, 
in some subjects, the majority of the on-therapy sequences are clonal genetically 
identical sequences, but these sequences are not found in circulating resting memory 
CD4+ T-cells [236]. The origin of these clonal sequences is unknown.  It could be 
either a long-lived cell that continues to release virions for a long time during cART or 
a large population of cells infected by the same variant where individual cells are 
reactivated and release HIV-1 for a short while before it dies, or a progenitor cell with 
HIV-1 DNA integrated that divides and where the progeny produce virions for a short 
while before it dies. The CD34+ hematopoetic progenitor cells have been suggested to 
be infected with HIV-1 and to serve as a reservoir during suppressive cART possibly 
the source of this clonal variant [254-256]. But recent reports using very sensitive 
sorting techniques to ensure that the population of cells analyzed is not contaminated  
have not found any signs of infection of CD34+ hematopoetic progenitor cells making 
this less likely [62, 257]. The reservoir is established early during infection which is 
demonstrated by the fact that subjects who start treatment during the first months of 
infection nevertheless experience viral rebound if treatment is stopped [258]. 
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1.5.3 Molecular basis of persistence 
It is generally believed that HIV-1 latency is established through the infection of CD4 + 
T-cells that, after HIV-1 DNA is integrated, return to a resting state. Resting memory 
CD4+ T-cells are not very susceptible to infection [259, 260]. Several mechanisms 
contribute to maintaining latency on a molecular level:  
 
 One of these mechanisms is the formation of specific nucleosomes. A 
nucleosome consists of DNA wrapped around histone proteins. Two 
nucleosomes consistently form within the 5’ of the LTR and thereby regulate 
transcription activity since they overlap with the binding site of many key 
transcription factors. Maintenance of the nucleosomes is highly dependent on 
the state of histone aceytlation which is reflected in that histone deacetylase 
inhibitors (HDACi) lead to remodeling of the nucleosomes which promotes 
HIV-1 transcription [261, 262]. In addition, HDACi promote transcription by 
increasing the recruitment of RNA Pol II to HIV-1 LTR [263].  
 DNA methylation at the site of HIV-1 transcription initiation is another 
mechanism by which HIV-1 remains latent and inhibitors of DNA methylation 
such as aza-Cdr can promote HIV-1 transcription [264, 265].  
 The initiation of HIV-1 transcription is dependent on several cellular 
transcription factors, most notably NF-кB and NFAT, in resting memory cells 
these transcription factors are not present in the nucleus, they reside in the 
cytoplasm and thereby also contribute to latency [266].   
 
1.5.4 Persistence in the CNS 
Antiretroviral therapy that reduces HIV-1 RNA levels in the plasma also leads to 
reduced HIV-1 RNA levels in the CSF in most subjects [160, 267]. Up to ten percent of 
infected individuals suppressed in the blood however continue to have detectable HIV-
1 RNA in CSF as measured by standard assays [268]. As CSF HIV-1 RNA levels 
become suppressed, markers for inflammation of the CNS such as CSF T-cell 
activation, CSF white blood cell count and CSF neopterin (a marker for macrophage 
activation) become normalized [267, 269, 270]. Even though CSF neopterin is reduced  
by cART it remains above what is seen in uninfected individuals, in particular it is 
elevated in those where CSF HIV-1 RNA is detectable by standard or sensitive assays 
[271, 272]. Markers for neural damage such as CSF NFL and CSF tau protein are also 
reduced during suppressive therapy [273].  The beneficial effects of cART on the CNS 
are seen in large cohort studies as a large reduction in the incidence of HIV-associated 
dementia in individuals receiving cART [274, 275]. An asymptomatic or mild cognitive 
impairment could continue to develop even during cART, possibly due to continual low 
grade inflammation, although this remains unresolved [271, 275, 276]. The degree of 
mild cognitive impairment seen in some HIV-1 infected individuals is correlated to  
nadir CD4+ T-cell count which might argue that the damage was done in the past 
[277].  
 
The CNS is separated from the blood by the blood-brain barrier. Due to their molecular 
size or hydrophilicity some ARVs do not penetrate the CNS very well. This has raised 
the suspicion that the CNS might be a “sanctuary site” where HIV-1 can continue to 
replicate despite cART. Letendre and colleagues have proposed a system to estimate 
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how well the different ARVs penetrate into the CNS; the CNS penetration effectiveness 
(CPE) scoring system (Table 4) The efficacy of the treatment regimen is then 
calculated by adding the CPE-score of each drug in the treatment regimen [278]. It is 
not clear if treatment regimens with a higher CPE lead to a more successful suppression 
of CSF HIV-1 RNA levels [268, 279, 280]. Neither is it established that higher CPE 
scores translate into an improved neurocognitive outcome [280-282].  
 
Table 4. CNS penetration effectiveness (CPE) scoring system adapted from [177].  
 
Increasing CNS penetration → 0 0.5 1 
Nucleoside reverse transcriptase 
inhibitors 
Didanosine Emtricitabine Abacavir 
Tenofovir Lamivudine Zidovudine 
Zalcitabine Stavudine  
Adefovir   
Nonnucleoside reverse 
transcriptase inhibitors 
 Efavirenz Delavirdine 
Nevirapine 
Protease inhibitors Nelfinavir Amprenavir Amprenavir/r 
Ritonavir Atazanavir Atazanavir/r 
Saquinavir Fosamprenavir Fosamprenavir/r 
Saquinavir/r Indinavir Indinavir/r 
Tipranavir/r  Lopinavir/r 
Entry inhibitors Enfuvirtide  Maraviroc 
T-1249 Vicriviroc 
Integrase inhibitors  Raltegravir  
Elvitegravir   
 
1.5.5 Eradication strategies 
In 2009 it was reported that a man had seemingly been cured of his HIV-1 infection 
[283]. He was doing well on suppressive therapy when he developed acute myeloic 
leukemia for which he received myeloablative treatment and allogenic stem cell 
transplantation from an individual homozygous for a deletion in the gene that encodes 
for CCR5. This lead to the complete remission of his leukemia and when his cART was 
discontinued HIV-1 RNA levels did not increase in blood. Even after five years without 
therapy he did not have any detectable virus in the plasma by standard assays [284]. 
Using several very sensitive assays it was, however, possible to detect HIV-1 RNA in 
plasma and HIV-1 DNA in the rectum, although at levels much lower than seen in 
subjects on suppressive therapy.  These very low levels of HIV-1 RNA and DNA could 
also possibly have been the result of contamination in the laboratory [285]. Since he 
remains disease free and HIV-1 RNA levels have not increased in his blood this can 
nevertheless be considered to be the first example of a functional cure of HIV-1 
(functional meaning that not all HIV-1 has been eradicated but HIV-1 RNA levels do 
not increase despite the discontinuation of cART). Follow-up studies have shown that 
myeolablative treatment followed by autologuos stem cell transplantation is not enough 
to achieve a cure [286]. Myeolablative treatment with allogenic stem cell 
transplantation from wild type CCR5 donors without the discontinuation of cART did 
however lead to undetectable HIV-1 RNA and DNA in PBMCs, CD4+ T cells and 
plasma, in the two subjects studied [287]. Recently it was also reported at the 7
th
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prevention in Kuala Lumpur, Malysia, that these two individuals had now stopped 
cART for several weeks without experiencing an increase in HIV-1 RNA levels in their 
plasma. Myeloablative treatment is associated with severe side effects and risks and 
other options need to be explored for eradicating HIV-1. Current HIV-1 therapy is life-
long, costly and not without side effects so a cure would be valuable from both an 
individual perspective as well as from a public health perspective. 
 
Most HIV-1 eradication strategies are based on the hypothesis that suppressive therapy 
prevents infection of new cells but does not cure HIV-1 since it remains latent in long-
lived cells. These cells produce low amounts of virions that cause viral rebound when 
treatment is stopped. Therefore, all latently infected cells capable of producing 
infectious virions need to be eliminated. By reactivating all the cells that are latently 
infected it is presumed that they would die, either from the cytopathic effect of viral 
replication or from the immune response directed against them. If this is done during 
suppressive therapy no new cells would be infected. Global T-cell activation by IL-2 
and CD3 antibodies without the discontinuation of cART have been tried but were 
associated with severe side effects and failed to deplete the HIV-1 reservoir [288-292].  
A possible explanation for why this strategy failed is that it caused clonal expansion of 
latently infected CD4+ T-cells of which a small fraction was not killed and were able to 
return to a resting state.   
 
HDACi have been studied intensely, with the hope that they would more selectively 
reactivate latent HIV-1, and initially it was reported that valproic acid, a weak HDACi, 
lead to a modest decrease in the reservoir size [293]. Follow-up studies did however 
show that this was not a durable effect [294, 295]. A recent trial with the more potent 
HDACi, vorinostat without the discontinuation of cART, showed an increase in cell 
associated HIV-1 RNA in CD4 + T-cells as a marker for increased transcription but did 
not lead to an increase in plasma HIV-1 RNA levels  measured with a sensitive assay 
[296]. Other studies with more potent HDACi:s are ongoing.  
 
Screening in cell lines has found other compounds that reactivate HIV-1 without global 
T-cell activation. One such compound called disulfiram, which is approved for the 
treatment of alcoholism, reactivates HIV-1 and a clinical trial of this compound is 
ongoing [297, 298]. Another substance that has been shown to lead to increased levels 
of HIV-1 RNA in plasma during suppressive therapy as a sign of reactivation of HIV-1 
is intravenously administered immunoglobulin [299].  
 
It is uncertain if reactivation of latent HIV-1 is enough to kill the latently infected cells 
and eliminate the reservoir. A dual approach where a therapeutic vaccination where 
cytotoxic T-cells are stimulated with an HIV-1 antigen before reactivation of latent 
HIV-1 to ensure killing of reactivated infected cells have been shown to be more 
effective in vitro and maybe a combination of therapeutic vaccination and reactivation 
will also be needed in vivo [300]. 
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1.5.6 Measuring the reservoir 
A challenge with trials for HIV-1 eradication is how to determine if the virus has been 
eradicated. New compounds can first be tested in vitro in cell lines where HIV-1 DNA 
is integrated [301]. If these new compounds reactivate HIV-1 in vitro and are shown to 
be safe to use in vivo then their effectiveness must be tested in clinical trials. The 
ultimate end-point is the cessation of cART without an increase of HIV-1 RNA levels 
in plasma. However secondary outcome measurements are also needed since cessation 
of therapy is not always feasible and may be associated with risks such as the 
development of drug resistance. It is also necessary to estimate the relative 
effectiveness of compounds that are partially effective in order to choose which 
strategies to pursue. Several approaches have been developed to measure the size of the 
reservoir and the degree of reactivation. What is considered to be the gold standard is 
the viral outgrowth assay. In this assay resting CD4+ T-cells are, using a limiting 
dilution approach, co-cultured with PBMCs during global T-cell activation. HIV-1 
antigen p24 can then be detected where latent HIV-1 was reactivated. Thereby, it is 
possible to determine the frequency of latently infected cells able to produce infectious 
virions [302]. Although a simplified version of this method was recently developed it is 
still relatively costly and time consuming [303]. A more feasible method to measure the 
size of the reservoir is to measure proviral HIV-1 DNA in a quantified number of 
resting CD4+ T-cells which can be done using various methods [304, 305].  
Unfortunately these methods do not correlate well to the outhgrowth assay [306]. In 
general they are showing >100 fold higher infection frequencies although this 
relationship is highly variable. This lack of correlation between the measurement of 
integrated HIV-1 DNA and the outgrowth assay may be due to the fact that most 
latently infected cells are not able to produce infectious virions since the integrated 
HIV-1 DNA are hypermutants, or contain lethal insertions or deletions. In addition, the 
outgrowth assay correlates poorly to  measurement of low levels of HIV-1 RNA in the 
plasma using the single-copy assay (SCA) [306]. Therefore the viral outgrowth assay is 
still the best assay to measure the effect of eradication efforts but since reactivation 
leads to transcription of HIV-1 RNA and production of virions SCA and other sensitive 
methods for HIV-1 RNA quantification can be valuable in measuring the degree of 
reactivation.  
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2 AIM 
To characterize HIV-1 infection of the CNS during suppressive therapy. 
 
Specific aims: 
 
Paper I: To study how well elite controllers control HIV-1 infection of the central 
nervous system (CNS) by measuring HIV-1 RNA levels in the cerebrospinal fluid 
(CSF). 
 
Paper II: To measure CSF and plasma HIV-1 RNA levels in subjects on 
suppressive therapy and to determine if the occurrence of HIV-1 in CSF during 
suppressive therapy is correlated to inflammation in the CNS. 
 
Paper III: To determine if the HIV-1 populations in CSF and plasma are 
genetically distinct during suppressive therapy indicating that they were produced 
by different populations of cells. 
 
Paper IV: To examine if the HIV-1 RNA levels in CSF during suppressive cART 
are reduced by treatment intensification with raltegravir.  
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
In paper I we analyzed 28 CSF samples and 27 concurrent plasma samples from 14 
subjects. The subjects had been classified as elite controllers since they, over a period 
of more than 12 months, had had three or more longitudinal plasma HIV-1 RNA 
determinations <40 copies/mL in the absence of cART. These samples were obtained 
from observational studies at the San Francisco General Hospital, University of 
California San Francisco (UCSF), San Francisco, USA. 
 
In paper II we analyzed 76 pairs of CSF and plasma samples from 45 HIV-1 infected 
subjects with <40 copies of HIV-1 RNA/mL in both CSF and plasma. These samples 
were obtained from observational studies at the Sahlgrenska University Hospital, 
Gothenburg, Sweden and San Francisco General Hospital, UCSF, San Francisco, USA. 
 
In paper III we analyzed 70 CSF and 29 plasma samples and the corresponding pre-
therapy samples from 17 subjects on suppressive therapy. Twelve subjects had started 
treatment during chronic infection and five during early infection (a median of 61 days 
after the estimated day of infection). These samples were obtained from observational 
studies at the Sahlgrenska University Hospital, Gothenburg, Sweden and San Francisco 
General Hospital, UCSF, San Francisco, USA. 
 
In paper IV we analyzed 63 paired CSF and plasma samples from 17 subjects. 
Samples were obtained from subjects enrolled in a clinical trial at San Francisco 
General Hospital, UCSF, San Francisco, USA. This was an open label 1:1 randomized 
clinical trial where subjects on suppressive cART were randomized to receive either 
placebo or the integrase inhibitor raltegravir for 12 weeks. Those randomized to receive 
placebo were offered to roll over to the raltegravir group after 12 weeks. 
 
3.2 ETHICAL CONSIDERATIONS 
All subjects participating in these studies gave written informed consent. The studies 
were approved by the regional ethical review board in Stockholm and Gothenburg, 
Sweden and by the institutional review board at UCSF, San Francisco, USA. 
 
3.3 LABORATORY METHODS 
3.3.1 Single-copy assay  
In papers I, II and IV we used the single-copy assay (SCA) to measure HIV-1 RNA 
levels in CSF and plasma (Figure 7). The sensitivity of assays used in clinical practice 
has continuously increased as new assays have been developed. Currently the lower-
limit of detection for clinical assays varies between 20-50 copies of HIV-1 RNA/mL. 
SCA was developed to study HIV-1 RNA concentrations in the range below this and 
can quantify HIV-1 RNA levels down to 0.3 copies of HIV-1 RNA/mL using a starting 
volume of 7 mL [307].  
  
 
   25 
 
 
Figure 7.  Single-copy assay.  
 
Samples are initially spiked with a known quantity of replication-competent avian 
sarcoma leukosis virus long terminal repeat with a splice acceptor (RCAS) which is a 
replication competent vector derived from an avian retrovirus. This is used as internal 
standard to ensure that the extraction process is successful. After adding the internal 
standard the samples are subjected to a pre-spin for 10 minutes to remove cellular 
debris that might interfere with the PCR-reaction. The samples are then ultra-
centrifuged at > 100 000 x g for 30 minutes to spin down the virions. The supernatant is 
removed and proteinase K is added to dissolve the virion. RNA is extracted with 
guandinium isothyocynate and glycogen. Isopropanolol is added and the lysate is 
centrifuged to create a pellet. The supernatant is removed and the pellet is cleaned with 
ethanol to remove any remaining isopropanolol since it inhibits PCR. The extracted 
nucleic acids were dissolved in 5 mM Tris-HCl containing dithiothretiol and an RNase 
inhibitor to prevent degradation. The samples are placed on a 96-well plate together 
with samples with known RCAS and HIV-1 concentrations to be used as standard 
curves. Each sample is distributed over six wells, HIV-1 RNA is quantified in triplicate, 
RCAS is quantified in duplicate and one well is analyzed for HIV-1 DNA by using a 
mix that does not contain RT during cDNA-synthesis. This setup makes it possible to 
analyze eight samples per plate of which two are the negative and positive controls. 
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The entire plate is subjected to cDNA-synthesis. After that a second mix that contains 
specific primers and probe for a conserved fragment of the gag region of HIV-1 and 
second set of primers and probe for the gag region of RCAS. The plate is then 
subjected to real-time PCR. Samples where less than half of the added amount of 
RCAS is detected, either due to poor extraction or interference with the PCR, are 
considered a failure and excluded from further analysis. A mean of the three wells per 
sample for HIV-1RNA quantification is calculated and if HIV-1 DNA is detected that 
amount is subtracted since measurement for HIV-1 RNA also will include HIV-1 DNA 
if present [307].  
 
To be able to calculate and compare median HIV-1 RNA levels in paper I, II and IV 
we attributed a value for negative samples that was 0.1 below the lower limit of 
detection for that sample. The lower-limit of detection varied depending on the starting 
volume [307].  
 
The SCA was carefully validated when developed [308]. We continuously monitored 
the sensitivity and precision of the assay by measuring the lower end of the standard 
curve for HIV-1. This was three samples that contained 3, 1 and 0.3 copies/mL 
respectively (Table 5). These standard curve-derived samples were measured in 
duplicate and not triplicate as clinical samples which likely contributed to a higher 
standard deviation (SD) than what was seen during the first validation of this assay 
[307].  
 
Table 5. Precision and sensitivity of SCA. 
 
 Estimated concentration   
(HIV-1 RNA/mL) 
Mean measured concentration*    
(HIV-1 RNA/mL, SD) 
Sensitivity                     
(% positive samples) 
0.3 0.5 (1) 30% 
0.78 0.8 (0.7) 
 1 2 (7.8) 52% 
1.56 2.5 (2.4) 
 3 3.2 (2.9) 94% 
3.125 3.5 (1.3)   
*Data from 94 runs of SCA where the standarad curve was further diluted down to 0.3 
copies/mL. Samples containing 3, 1 and 0.3 copies/mL were then analyzed in duplicate as 
internal control. Data in italics is included as comparison and were generated during the first 
validation of SCA (ref) by analyzing by ten runs of analyzing a diluted sample with known 
HIV-1 RNA concentraion, samples were analyzed in triplicate.  
 
3.3.2 Single-genome sequencing 
In paper III we used single-genome sequencing (SGS) to analyze the HIV-1 
populations in CSF and plasma (Figure 8). The advantage with SGS is that PCR re-
sampling and PCR induced recombination can be avoided, and it allows for the 
detection of minor variants. We analyzed CSF and plasma samples obtained before 
therapy was initiated or just after therapy was initiated but before suppression was 
achieved (hereafter referred to as pre-suppression) and compared these pre-suppression 
sequences to sequences from samples obtained during suppressive therapy. The SGS 
procedure used in this thesis was developed by Palmer and co-workers [308, 309]. In 
conducting this assay the samples are extracted according to the same procedure 
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described for SCA for samples containing <50 copies of HIV-1 RNA/mL. For samples 
with a higher HIV-1 RNA concentrations we used a similar approach with the 
exception that microcentrifugation was used instead of ultra-centrifugation to 
concentrate virions. After extraction cDNA is generated using random primers. The 
samples containing cDNA are then diluted and distributed over a 96-well plate so that 
less than 30% of the wells are positive after nested PCR for a 1.3 kb fragment (p6 
through nucleotide 1-900 of RT). Based on Poisson statistics the positive wells only 
contained one HIV-1 DNA molecule 80% of the time [308, 309]. Generated amplicons 
were then sent for sequencing.  
 
 
 
Figure 8. Single-genome sequencing. Viral RNA is extracted and converted to cDNA. The sample is 
then diluted and distributed over a 96 well plate until less than 30% of the wells yield a product after 
nested PCR to ensure that a maximum of one HIV-1 DNA molecule was present in each well. The 
amplified product is then sequenced and phylogenetic analyses can take place.  
 
 
3.3.3 Sequences analyses 
For paper III the raw sequence data were assembled using an in house Perl script. 
Alignments were constructed using MAFFT version 6.0 
(http://mafft.cbrc.jp/alignment/software/).  We used several strategies to ensure a high 
sequence quality. 
 
1. Contigs were required to have a bidirectional sequence reads of at least 1.1 kb. 
2. Contigs containing more than one single-nucleotide polymorphism were 
removed since this indicated amplification of more than one single cDNA 
template. 
3.  Contigs were scanned by eye and trimmed and edited when deemed necessary. 
 
Before we continued with further analyses we constructed an alignment with all 
sequences and created a neighbor-joining tree to make sure that sequences from each 
subject clustered with each other, which would be an indication of contamination or 
mislabeling.  
 
We scanned the alignments for hypermutants using the on-line tool “Hypermut” 
(http://www.hiv.lanl.gov/content/sequence/HYPERMUT/hypermut.html) [310]. We 
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compared the proportion of hypermutants in CSF and plasma and then the 
hypermutants were removed from the alignments. Alignments were tested for 
recombinants using Splitstree4 (http://www.splitstree.org/) and recombinants were 
removed [311].   
 
We used the Slatkin-Maddison method as implemented in HyPhy version 2.1.2 to test 
for compartmentalization in pre-suppression samples (http://hyphy.org/) [312].  Ten 
thousand permutations were performed and p-values <0.05 were considered significant 
evidence for compartmentalization.  
 
To determine the relationship of pre-suppression and on-therapy CSF and plasma 
sequences for each subject we constructed phylogenetic trees.  Maximum likelihood 
trees were constructed using PhyML 3.0 (http://www.atgc-montpellier.fr/phyml/) [313]. 
The model of evolution was selected using the Find model tool on Los Alamos HIV 
Sequence Database (http://www.hiv.lanl.gov/content/index). Statistical support of the 
tree structures was obtained by 200 bootstrap replicates. Bootstrap values over 90% 
(180/200) were considered significant. Trees were rooted with a pre-suppression 
plasma sequence. 
 
HIV-1 genetic diversity (average pairwise distance, APD) was calculated using the p-
distance model in MEGA5.0 (www.megasoftware.net) [314].  
 
3.3.4 Markers for immune activation  
CSF white blood cell counts and differential and blood CD4+ T-cell analysis were all 
performed in the Sahlgrenska Hospital in Gothenburg or the San Francisco General 
Hospital Clinical Laboratories using standard clinical methods. Neopterin was 
measured in cell-free CSF by enzyme-linked immunoassay according to the 
manufacturer’s instructions (BRAHMS Aktiengesellschaft, Henningsdorf, Germany) in 
Innsbruck, Austria. Normal reference values were <5.8 nmol/L in CSF [315].  
 
3.3.5 T-Cell activation by flow cytometry 
CSF and blood CD41+ and CD81+ T-cell activation were assessed by the percentage of 
cells in fresh specimens co-expressing surface CD38 and human leukocyte antigen 
(HLA)–DR or CCR5 as described previously [270, 316]. Flow cytometry data were 
compensated and analyzed with FlowJo (Tree Star) software version 8.8 in San 
Francisco, USA. 
 
3.3.6 Neurological evaluations 
Neurological performance was monitored using four brief quantitative tests (timed gait, 
grooved pegboard, finger tapping, and digit symbol) to obtain a simple aggregate 
quantitative neurological performance z score (QNPZ-4) [317, 318]. 
 
3.3.7 Statistical methods 
Means, SD, median and intra-quartile range (IQR) were calculated. Variables were 
compared by Mann-Whitney’s test, an unpaired nonparametric t-test. Proportions 
were compared using Fisher exact test. All p-values were 2-sided with values <0.05 
considered significant. Statistical analyses were performed using Excel (Microsoft) 
and GraphPad Prism 6 (GraphPad).  Graphs were constructed using GraphPad Prism 
6 (GraphPad). 
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4 RESULTS AND DISCUSSION 
 
In paper I we employed SCA to measure the HIV-1 RNA levels in CSF and plasma of 
elite controllers and found that HIV-1 RNA can be detected in the 19% of the CSF 
samples which was significantly less than the 54% of the plasma samples that were 
positive. The levels of HIV-1 RNA were also significantly lower in CSF than in 
plasma. 
 
We analyzed 28 CSF samples and 27 concurrent plasma samples from 14 elite 
controllers. Three samples were excluded because of internal standard failure. HIV-1 
RNA was detected in only 5 of 26 CSF samples compared to 14 of 26 plasma samples 
(P=0.02). The median levels were 0.2 (range 0.1-6) copies/mL in CSF compared to 0.8 
(range 0.1-189) in plasma (P<0.0001).  
  
A previous study, using an assay with a lower-level of detection of 2.5 copies/mL, 
showed that none of the eight elite controllers examined had detectable CSF HIV-1 
RNA and the level of intrathecal immune activation was comparable to what is seen in 
those that are not infected by HIV-1 or HIV-1 infected subjects on suppressive therapy 
[319]. In contrast to the previous report could we detect low levels of CSF HIV-1 RNA 
in 5 of 14 elite controllers making our study the first, to our knowledge, to detect HIV-1 
RNA in the CSF of elite controllers. That the proportion of samples where CSF HIV-1 
RNA could be detected and the levels measured in the CSF are significantly lower than 
in plasma is similar to what we and others have found in untreated and treated HIV-1 
infected subjects (paper II, paper IV [159, 160, 163]). Whether the infrequent and low 
amounts of HIV-1 in the CSF reflect production within the CNS or virion exchange 
between CSF and the blood is uncertain. That HIV-1 RNA could be detected in plasma 
of most elite controllers with sensitive methods is comparable to what other studies 
have shown [147]. It has been shown that HIV-1 in the blood of elite controllers can 
develop new immune escape mutations suggesting that source of the virions found, at 
least to some extent, must be ongoing replication with infection of new cells and 
production of virions from these cells [151]. 
 
A weakness of this study was that we did not ensure the primers and probe matched the 
viral strains by sequencing. In a previous report where this was done a primer or probe 
mismatch that was considered to be significant was found in 11% of the 62 elite 
controllers from where it was possible to obtain a sequence [147]. Our reported 
numbers could therefore underestimate the prevalence of HIV-1 RNA in CSF and 
plasma. 
 
In paper II we employed SCA to measure the HIV-1 RNA levels in paired CSF and 
plasma samples from 45 subjects on suppressive therapy. We found that 17% of the 
CSF samples contained low levels of HIV-1 RNA, which was significantly less than 
the 57% of the plasma samples where HIV-1 RNA could be detected. CSF HIV-1 RNA 
could be detected even after 10 years of suppressive therapy. The occurrence of CSF 
HIV-1 RNA was correlated to elevated levels of CSF neopterin, a marker for 
intrathecal immune activation.  
 
We analyzed a total of 76 pairs of samples (7 mL from each sample) from CSF and 
plasma from 45 subjects, including 18 with longitudinal samples. The extraction 
control failed for 14 of the 152 samples (8 plasma and 6 CSF); and they were excluded 
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from further analysis. Twelve of the 70 (17%) CSF samples were positive for HIV-1 
RNA which was significantly less than the 39 of 68 (57%) plasma samples that were 
positive (P=<0.0001). The median CSF HIV-1 RNA levels was 0.2 copies/mL (range 
0.2-3.9 IQR 0.2-0.2) compared to 0.3 copies/mL (range 0.2-15, IQR 0.2-0.9) in plasma 
(P=<0.0001). 
 
The significantly lower levels of HIV-1 RNA in CSF than in plasma is similar to the 
relationship which is seen during untreated HIV-1 infection where the levels of CSF 
HIV-1 RNA is usually ten-fold lower than in plasma although this relationship varies 
substantially between individuals [320]. The proportion of positive samples was similar 
to those that were seen in paper IV where 14% of the CSF samples and 64% of the 
plasma samples were positive. Previously it has been reported that on-therapy plasma 
HIV-1 RNA levels are correlated to pre-therapy plasma HIV-1 RNA levels [229].We 
did not find any correlation between the occurrence of CSF HIV-1 RNA and the pre-
therapy CSF or plasma HIV-1 RNA levels (P=0.41 and P=0.60). In addition, we did not 
find any correlation with between detectable plasma HIV-1 RNA and pre-therapy 
plasma HIV-1 RNA levels (P= 0.91). CSF HIV-1 RNA could be detected even after 
10 years of suppressive therapy and plasma HIV-1 RNA up to 11 years of 
suppressive therapy. That HIV-1 RNA can be detected even after years of suppressive 
therapy is consistent with a previous report were plasma HIV-1 RNA could be 
detected after 7 years of suppressive therapy [228]. 
 
A previous study has demonstrated that neopterin (a marker for macrophage activation) 
is elevated in the CSF of HIV-1 infected subjects even after years of suppressive 
therapy [271]. Furthermore it has been demonstrated that subjects on suppressive 
therapy with “CSF-escape” (>50 copies/mL in CSF while <50 copies/mL in plasma) 
have elevated levels of CSF neopterin compared to those with <50 copies/mL (a 
median of 9.2 nmol/L vs 5.1 nmol/L). In subjects with < 50 copies/mL in both CSF and 
plasma those with >2 copies/mL in the CSF also have elevated levels of CSF neopterin 
compared to those <2 copies/mL [272]. In agreement with these earlier findings, we 
found that CSF neopterin levels were higher (mean 7.4 compared to 5.8 nmol/L) in 
time points with detectable HIV-1 RNA in CSF (P=0.03). These findings suggest that 
even very low levels of HIV-1 in CSF during suppressive therapy are correlated to 
intrathecal inflammation. 
 
It has been suggested that the CNS is a “sanctuary site” where HIV-1 can continue to 
replicate during suppressive cART (plasma levels <20-50 copies/mL) since some 
ARVs are less effective in crossing the blood-brain barrier. The CNS penetration 
effectiveness (CPE) score was developed by Letendre and colleagues to calculate a 
rating of the estimated effect in CNS for each regimen [279, 321].  We did not find any 
difference in the CPE between time points with detectable CSF HIV-1 RNA to time 
points without detectable CSF HIV-1 RNA (P=0.59). This suggests that CPE is not a 
good measurement of the efficacy of a particular treatment regimen within the CNS or 
that there is no, or very little, ongoing replication in the CNS during therapy that is 
suppressive in both the CSF and plasma regardless of the CPE of the treatment regimen 
used.  
 
One limitation of our study was that we did not have access to pre-therapy samples to 
test for primer and probe mismatch neither did we ensure this by sequencing. Our HIV-
1 RNA determinations are therefore likely to be an underestimate since there was likely 
a primer/probe mismatch in some subjects.  
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In paper III we sequenced the HIV-1 populations in CSF and plasma during 
suppressive therapy. We found that a large fraction of CSF HIV-1 variants during 
suppressive therapy are replication-incompetent hypermutants. In one of the two 
subjects where we were able to obtain sequences from both CSF and plasma we found 
genetically distinct variants in CSF and plasma. 
 
Seventy CSF samples with viral RNA levels <40 copies/mL were selected for analysis 
(median volume 8 mL). From 15 of these 70 CSF samples we generated 21 amplicons. 
These 15 samples were collected from 8 of the 17 subjects in the study. Next we 
analyzed 29 on-therapy plasma samples (median volume 7 mL, range 5-14 mL) from 
these 8 subjects. From the 29 on-therapy plasma samples we generated 14 amplicons. 
We also analyzed plasma and CSF samples collected before or immediately after 
therapy initiation (pre-suppression samples).  
 
Sequence analyses revealed that 8 of 21 sequences obtained from the CSF during 
suppressive therapy were hypermutants compared to 0 of 13 sequences from plasma 
(P=0.013). Hypermutants are induced by a family of cellular cytidine deaminase 
referred to as the APOBEC-family and result in replication incompetent viral strains 
[322].  The high level of HIV-1 hypermutants in the CSF could possibly be explained 
by these virions being produced by a population of cells in the CNS more likely to 
produce hypermutants due to a high content of APOBEC. This finding should be 
interpreted with some caution due to the small number of subjects and due to that 6/13 
of the hypermutants found in CSF came from one subject. Furthermore, we had fewer 
on-therapy plasma-derived sequences than CSF-derived sequences (14 versus 23). 
 
In two of the subjects (7027 and 9058) where we generated sequences from both CSF 
and plasma during suppressive therapy, the on-therapy sequences from CSF and plasma 
did not cluster together. For subject 7027, CSF and plasma sequences from the same 
time point were separated by branches with significant bootstrap support (Figure 9). 
This is consistent with the hypothesis that these virions were produced by cells within 
the CNS and cells in the periphery (either the same or different type of cell) that had 
been infected with genetically distinct viral variants. But it is not conclusive evidence; 
it could also be explained by a population of cells in the periphery being infected with 
genetically distinct viruses producing virions of which some were transported into the 
CSF.  In the subjects where we had on-therapy CSF sequences from several time points 
these sequences did not cluster together and in some cases they were separated by 
branches with significant bootstrap support. Furthermore these sequences were not 
found on longer branches. The lack of evolution among on-therapy CSF sequences 
compared to pre-suppression sequences is consistent with what other studies have 
shown for blood and lymphatic tissue [233, 236-239]. These findings are consistent 
with the hypothesis that the virions found in CSF or plasma during therapy are 
produced by cells which had been infected before the initiation of cART and are 
reactivated during cART and then produce virions for a short period of time. 
 
This study had limitations. Notably, despite the analysis of a large number of CSF 
samples obtained during suppressive therapy we were unable to generate many 
sequences for phylogenetic analysis. This was due to the low levels of HIV-1 RNA in 
CSF during suppressive therapy and to the unexpected high amount of hypermutants. 
This, in itself is an interesting finding, unfortunately prevented an in-depth 
phylogenetic analysis.  
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Figure 9. Maximum likliehood tree made in PhyML 3.0 under the GTR+gamma nucleotide subsitution 
model. Sequences from plasma are represented by squares and sequences from CSF are represented by 
circles. The tree was rooted with a pre-suppression plasma sequence. Pre-suppression sequences are 
represented by black symbols for plasma and grey symbols for CSF. Longitudinal sequences obtained 
during full suppression are represented by colored symbols: time point 1 red; time point 2 green; time 
point 3 blue, and time point 4 purple. Branch support was calculated by 200 boot-strap replicates. 
Branches with a boot-strap support of 180 or more are marked with a star.  
 
In paper IV we found that treatment intensification with raltegravir did not affect the 
CSF HIV-1 levels or intrathecal immune activation in subjects whose treatment was 
intensified. 
  
When the HIV-1 RNA measurements for all the CSF and plasma samples from every 
phase of the clinical trial were combined we found that HIV-1 RNA could be detected 
in 14% (8/56) CSF samples compared to 64% (32/50) of the plasma samples 
(P<0.001). Median for all CSF samples was 0.2 copies/mL (IQR 0.2-0.4) whereas 
median for plasma samples was 0.9 copies/mL (IQR 0.3-2.2 copies/mL) (P<0.0001). 
Both the proportion of positive samples and the median concentrations in each fluid 
were comparable to what was reported in paper II.  
 
Treatment intensification did not reduce the proportion CSF samples where HIV-1 
RNA could be detected: in the group without treatment intensification the proportion 
was 2 of 15 and in the group with treatment intensification it was 5 of 23 (P=0.69). 
Treatment intensification did not affect the level of CSF neopterin (P=0.45). The lack 
of effect on CSF HIV-1 RNA concentrations and CSF neopterin by treatment 
intensification is comparable to what was seen in another study using either enfurvitide, 
maraviroc or lopinavir/ritonavir to intensify treatment over a shorter period of time (8 
weeks) and using a different assay for HIV-1 RNA quantification [323].  
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5 CONCLUSIONS AND FUTURE PERSPECTIVES  
 
In order to direct future attempts to eradicate HIV-1 it is important to clarify in which 
cells and in which parts of the body HIV-1 persists during suppressive therapy. It is 
also of interest to determine if there is ongoing infection of new cells during 
suppressive therapy since many eradication efforts are trying to achieve reactivation of 
all latent HIV-1 during cART with the assumption that cART will block infection of 
new cells. It has been suggested that the CNS could harbor latently infected cells during 
suppressive therapy.  It has also been proposed that there is ongoing replication within 
the CNS during suppressive therapy since some ARVs are less effective in crossing the 
blood-brain barrier. In this thesis we have studied HIV-1 in the CSF of elite controllers 
and subjects on suppressive therapy to further characterize HIV-1 infection of the CNS. 
One general caveat of these studies is that they have been conducted on CSF since it is 
more accessible than cells from the CNS. It should however be noted that what is seen 
in the CSF does not necessarily always accurately reflect processes in the CNS.  
 
Since elite controllers may be a model for a functional cure for HIV-1, we studied how 
they control HIV-1 infection of the CNS. We found that most elite controllers control 
HIV-1 infection of the CNS well with no, or very little, HIV-1 RNA present in the 
CSF. Contrary to previous reports, we found low levels of HIV-1 RNA in the CSF in 
some subjects demonstrating that cells in this compartment are infected, or can be at 
risk for infection since there occasionally is HIV-1 present in the CSF. Recent studies 
have indicated that it might be possible to induce elite control by the early initiation of 
cART [324, 325]. With the caveat that we studied “spontaneous elite controllers” and 
not “post-treatment elite controllers” the induction of elite control might be a possible 
strategy for a functional cure. Whether the HIV-1 RNA found in the CSF of elite 
controllers comes from virions produced by cells in the CNS or if it represents infected 
cells that have migrated to the CNS from the periphery remains unknown. Future 
studies should aim for sequencing the HIV-1 in CSF and plasma of elite controllers to 
determine the source of these virions, though this will require large volumes of plasma. 
It would also be of interest to study if “post-treatment elite controllers” are different 
than”spontaneous elite controllers”. 
 
We have also found that very low levels of HIV-1 can be detected in the CSF of 
subjects on suppressive therapy although at a lower frequency and lower levels than 
what is seen in the plasma (paper II, paper IV) and this is consistent with previous 
reports [272, 323]. We found that the occurrence of CSF HIV-1 RNA is correlated to 
intrathecal immune activation measured by CSF neopterin. If this CSF immune 
activation is shown to be correlated to the development of cognitive impairment other 
treatment strategies will need to be investigated. Since there does not seem to be any 
ongoing replication in the CNS during suppressive therapy it would not be meaningful 
to develop more potent ARVs, instead strategies to specifically decrease the 
inflammation in the CNS during cART should be explored.  
 
It remains unclear whether the virions found in CSF during suppressive therapy are 
produced in the CNS. We found one example of a subject that had genetically distinct 
variants in CSF and plasma during suppressive therapy. This is consistent with the 
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production of virions by cells within the CNS that had been infected by a genetically 
distinct HIV-1 population compared to the population that infected cells in the 
periphery but it is not conclusive evidence. It could also be due to the production of 
virions by cells in the periphery that had been infected by genetically distinct variants. 
Then some virions were transported into the CSF by chance and found there giving the 
impression of compartmentalization. If the compartmentalization between CSF and 
plasma was found in other subjects it would, however, support the hypothesis of virion 
production in the CNS during suppressive therapy. Future studies should try to generate 
more sequences by analyzing more samples with larger volume to further investigate 
the CSF HIV-1 population on-therapy. Currently there is a loss in sensitivity for SGS 
when one tries to amplify longer fragments. If future techniques allows for sequencing 
longer fragments without losing sensitivity this should be considered in order to 
generate a stronger phylogenetic signal to achieve a better phylogenetic resolution. 
Other assays to determine the origin of virions such as characterizing cellular markers 
on the envelope of the virion could also be explored to further elucidate the question of 
the origin of HIV-1 virions found in CSF during suppressive therapy. It would also be 
of interest to analyze cells from the CNS of HIV-1 infected subjects on suppressive 
therapy who died from other causes. Then it would be possible to compare the 
sequences from infected cells in the CNS (if there are any) to the sequences from 
virions found in CSF and plasma during suppressive therapy to determine their origin. 
 
If cells in the CNS produced virions during suppressive therapy this would mean that 
these cells would also need to be targeted in order to achieve a functional cure for HIV-
1. The first subject to have been reported to have been functionally cured from HIV-1 
did not have any HIV-1 RNA detectable in the CSF, even by single-copy assay, at 
follow up examinations [285]. Possibly he had had infected cells in the CNS that were 
eradicated during the treatment of his leukemia. When testing other compounds to 
eradicate HIV-1 one might need to take the CNS into account, either by designing 
drugs that penetrate well across the blood-brain barrier or by also administering them 
intrathecally, otherwise the infection might rebound from virions produced in the CNS. 
 
We found that a large fraction of the HIV-1 found in the CSF during suppressive 
therapy is replication incompetent hypermutants. This finding should be interpreted 
with some caution since many of the hypermutants in our study were found in one 
subject.  It could, however, be due to cells in the CNS, or cells that migrate into the 
CNS, contain more APOBEC than most other cells. We have also observed a lot of 
hypermutants in cells from the periphery in subjects on suppressive therapy 
(unpublished data) and this has also been reported by others [326]. Why a lot of HIV-1 
variants found during suppressive therapy are hypermutants is unclear. Perhaps cells 
containing replication competent virus are more likely to be cleared and therefore cells 
containing hypermutants accumulate over time.  
 
We did not observe any signs of evolution among CSF sequences found during 
suppressive therapy compared to pre-suppression sequences. This is consistent with 
what most studies have observed in blood and lymphatic tissue [233, 236-239]. The 
level of HIV-1 RNA in the CSF was not affected by treatment intensification. This is 
consistent with what most studies have reported for HIV-1 RNA in plasma and with the 
findings of one previous study on CSF [240-243, 323]. The lack of effect by treatment 
intensification and the absence of viral evolution do however not rule out the possibility 
of ongoing replication. The power to detect evolution in the CSF was limited by the 
number of sequences found and future studies should try to generate more sequences by 
analyzing more samples with larger volume. Also, new techniques that allow for 
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sequencing of longer fragments without loss of sensitivity would be useful. The power 
to detect a decrease in CSF HIV-1 RNA levels during treatment intensification is 
limited by the sample size, biological variation and assay variability. Perhaps larger 
studies would show that there is indeed a small reduction in the CSF HIV-1 RNA 
concentrations by treatment intensification, in all, or in a subset, of subjects. New 
techniques that allow for a more precise quantification of HIV-1 to minimize assay 
variability would also be useful for treatment intensification studies. 
 
In conclusion, HIV-1 can be detected in the CSF even after years of suppressive 
therapy. The detection of HIV-1 in the CSF is correlated to intrathecal immune 
activation. The HIV-1 found in the CSF during suppressive therapy might be produced 
by cells in the CNS that need to be targeted in order to cure HIV-1. Since there are no 
signs of viral evolution among sequences found in the CSF during suppressive therapy 
and the CSF HIV-1 RNA levels are not affected by treatment intensification there does 
not appear to be any ongoing replication in the CNS during suppressive therapy.  
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